BioNumerik’s Tavocept Fails In Neuropathy, Adds To Survival Time
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is looking for commercialization partner for cancer candidates, CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
BioNumerik Launches Phase III Trial To Confirm Surprising Tavocept Survival Benefit In NSCLC
Meta-analysis of secondary endpoint data from earlier chemoprotection trials revealed as much as 6.7 months survival benefit compared to one or two months with current regimens.
BioNumerik Launches Phase III Trial To Confirm Surprising Tavocept Survival Benefit In NSCLC
Meta-analysis of secondary endpoint data from earlier chemoprotection trials revealed as much as 6.7 months survival benefit compared to one or two months with current regimens.
Takeda/BioNumerik’s Tavocept Phase III Data Did Not Meet Primary Endpoints
Takeda will consider terminating its licensing and development agreement for the investigational drug.